Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Feed Symbols: NVCR

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Piper Sandler Maintains Neutral on NovoCure, Raises Price Target to $80

By Benzinga Newsdesk
January 17, 7:48 AM
Piper Sandler analyst Jason Bednar maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $70 to $80.

NVCR

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

JP Morgan Maintains Neutral on NovoCure, Raises Price Target to $99

By Benzinga Newsdesk
January 6, 12:07 PM
JP Morgan analyst Jessica Fye maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $86 to $99.

NVCR

Read More
20 minute read
  • Analyst Ratings
  • Downgrades
  • Initiation
  • Intraday Update
  • Upgrades

Benzinga’s Top Ratings Upgrades, Downgrades For January 6, 2023

By Benzinga Insights
January 6, 11:00 AM
Upgrades Piper Sandler upgraded the previous rating for Aligos Therapeutics Inc (NASDAQ:ALGS) from Neutral to Overweight. Aligos Therapeutics…

AGTI

Read More
2 minute read
  • Earnings
  • Markets
  • News
  • Penny Stocks
  • Small Cap

Tesla, Amazon, Aehr, Silvergate, Novocure: Why These 5 Stocks Are Drawing Investors’ Attention Today

By Bhavik Nair
January 5, 8:57 PM
Major Wall Street indices closed over 1% lower on Thursday, dragged by strong employment data which could nudge the Federal Reserve to continue its rate hikes.

AEHR

Read More
3 minute read
  • Commodities
  • Earnings
  • Eurozone
  • Global
  • Intraday Update
  • Markets
  • News
  • Penny Stocks
  • Small Cap

Dow Falls Over 200 Points; Walgreens Earnings Top Expectations

By Lisa Levin
January 5, 3:42 PM
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 200 points on Thursday.

ABVC

Read More
3 minute read
  • Commodities
  • Earnings
  • Eurozone
  • Global
  • Intraday Update
  • Markets
  • News
  • Penny Stocks
  • Small Cap

Nasdaq Down Over 100 Points; Crude Oil Rises 1%

By Lisa Levin
January 5, 1:13 PM
U.S. stocks traded lower midway through trading, with the Nasdaq Composite shedding more than 100 points on Thursday.

ABVC

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

Novocure Stock Surges As Tumor Treating Fields Shows Overall Survival In Lung Cancer Patients

By Vandana Singh
January 5, 11:21 AM
Zai Lab Limited (NASDAQ:ZLAB) and Novocure Ltd (NASDAQ:NVCR) announced that the LUNAR study met its primary endpoint, demonstrating a statistically significant and…

NVCR

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

Novocure Announces Pivotal LUNAR Study In Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

By Benzinga Newsdesk
January 5, 8:05 AM
The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival The full LUNAR data will be presented at a future medical congress Novocure

NVCR

Read More
4 minute read
  • Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights
December 23, 2:35 PM
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ALGN

Read More
1 minute read
  • Analyst Ratings

Where NovoCure Stands With Analysts

By Benzinga Insights
November 29, 1:02 PM
Analysts have provided the following ratings for NovoCure (NASDAQ:NVCR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

NVCR

Posts navigation

1 2 … 8 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service